The drug, Leqembi, has been shown to slow the decline in memory and thinking that defines Alzheimer’s. But there are risks, including the need for infusions and the possibility of brain swelling.
U.S. health officials on Friday approved a closely watched Alzheimer’s drug that modestly slows the brain-robbing disease, albeit with potential safety risks that patients and their doctors will have to carefully weigh.U.S. health officials on Friday approved a closely watched Alzheimer’s drug that modestly slows the brain-robbing disease, albeit with potential safety risks
Leqembi, from Japan’s Eisai and its U.S. partner Biogen, is a rare success in a field accustomed to failed experimental treatments for the incurable condition Leqembi, from Japan’s Eisai and its U.S. partner Biogen, is a rare success in a field accustomed to failed experimental treatments for the incurable condition. The delay in cognitive decline brought about by the drug likely amounts to just several months, but Dr. Joy Snider and some other experts say it could still meaningfully improve people’s lives.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
FDA approves Leqembi, Alzheimer's drug that modestly slows diseaseALZHEIMER'S DRUG: The drug, Leqembi, is the first that’s been convincingly shown to slow the decline in memory and thinking that defines Alzheimer’s by targeting the disease's underlying biology. MORE:
Read more »
Second Alzheimer’s treatment showing modest benefits for patients approved by FDAThe FDA has granted accelerated approval to a second Alzheimer’s drug that trial data show offers modest benefits to patients.
Read more »
US approves breakthrough drug Leqembi to treat Alzheimer'sLeqembi and Aduhelm, which were jointly developed by Japan's Eisai and Biogen of US 'represent an important advancement in the ongoing fight to effectively treat Alzheimer's disease,' says Food and Drug Administration.
Read more »
Alzheimer’s drug that slows cognitive decline gets FDA approvalThe drug, lecanemab, removes a sticky protein from the brain called amyloid beta, which is thought to play a key role in the memory-robbing illness.
Read more »
FDA Approves Alzheimer's Drug That Modestly Slows DiseaseThe drug, Leqembi, is the first that’s been convincingly shown to slow the decline in memory and thinking that defines Alzheimer’s.
Read more »
FDA OKs Alzheimer’s drug that modestly slows disease“This drug is not a cure. It doesn’t stop people from getting worse, but it does measurably slow the progression of the disease,” said Dr. Joy Snider, a neurologist at Washington …
Read more »